The available data indicate that a highly effective vaccine to combat hepatitis B has been developed. In a well-controlled, double-blind clinical study of a high risk group (male homosexuals), this vaccine stimulated the production of anti-HBs in more than 92% of the test group followed for two years. As a generalization, this new vaccine can be described as highly effective, safe, stable, and a welcome addition to preventive medicine. Dentists, in particular oral surgeons and periodontists, are in a high risk category with respect to hepatitis B exposure. This vaccine deserves considerable attention by these groups. All members of the dental profession should seriously consider the use of this vaccine as a personal and public health measure when it becomes commercially available.